In this issue:
Brain TSPO-PET predicts later disease progression independent of relapses in MS
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in MS
Optic nerve region assessed by VEP in MS diagnosis
Siponimod and cognition in SPMS
Effects of ibudilast on MRI measures
COVID-19 in MS patients: Susceptibility, risk factors and serological response
Anti-MOG antibody-associated disorders: Differences in clinical profiles and prognosis in Japan and Germany
Discontinuation of DMTs for MS in patients aged over 50 with disease inactivity
Parity and disability progression in RRMS
Efficacy of alemtuzumab in RRMS patients who received additional courses after the initial two courses
Please login below to download this issue (PDF)